Gilead Sciences (GILD) Announces FDA Approval of Letairis Combo as PAH Treatment
Tweet Send to a Friend
Gilead Sciences (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Letairis (ambrisentan) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
